89bio (ETNB) said Thursday it negotiated with lenders a $50 million increase in its borrowing capacity.
The biotechnology company said in a regulatory filing with the Securities and Exchange Commission that its lenders amended an existing term loan agreement to $150 million from $100 million. The term loan is set to expire on Oct. 1, 2028.
89bio received $35 million at closing, and will have an additional $35 million available through June 30, 2025.
A second tranche of $30 million will be funded once a certain, time-based clinical milestone is met, while a further $50 million will be made available subject to lenders' due diligence, the company said.
As part of the agreement, 89bio also issued 406,951 warrants to K2 HealthVentures exercisable at $7.3719 each.
Price: 7.17, Change: -0.09, Percent Change: -1.21
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。